70 citations
,
April 2013 in “Endocrine” This review found that lifestyle changes, such as diet and exercise, are beneficial for managing metabolic and endocrine abnormalities in obese patients with PCOS and suggests combining these with anti-obesity agents for enhanced effects.
9 citations
,
August 2024 in “Australian Prescriber” This review highlights that pharmacotherapy for polycystic ovary syndrome should address individual patient concerns, with metformin beneficial for reducing weight and metabolic risk, and lifestyle modifications also important.
4 citations
,
November 2012 in “Obstetrics, Gynaecology & Reproductive Medicine” This review describes therapeutic strategies for polycystic ovary syndrome, highlighting current treatments for ovulation induction and emphasizing lifestyle changes and personalized approaches, but reports no new clinical results.
815 citations
,
April 2010 in “The Journal of Clinical Endocrinology & Metabolism” This review examines the relationship between polycystic ovary syndrome and cardiovascular disease risk, but reports no new clinical findings; the panel calls for guidelines to prevent CVD in this population.
36 citations
,
July 2020 in “Frontiers in Medicine” Spironolactone might help protect against severe lung problems in COVID-19 patients.